### Atrial Fibrillation (Non-valvular): prescriber decision support on anticoagulation

### Contents

Assessing patients for anticoagulation in AF	Page 2
Patient factors and anticoagulant choice	Page 3
Checklist for initiation	Page 4
DOAC monitoring and reviewing	Page 5
DOAC- further information on calculating CrCl	Page 6
Points for discussion during DOAC review	Page 6
Criteria for review and discontinuation of DOACs	Page 6
Warfarin monitoring and reviewing	Page 7
References	Page 8
Appendix 1: Anticoagulation comparison table	Page 9
Appendix 2: Warfarin	Page 13
Appendix 3: Switching anticoagulation therapy (for AF only)	Page 14
Appendix 4: Notes on HASBLED	Page 15


#### Scope:


This document is intended as prescriber decision support for prescribing anticoagulants for patients with non-valvular AF. The diagnosis and management of atrial fibrillation is beyond the scope of this document and prescribers are referred to the full <u>NICE clinical guidance</u> or NICE Pathway. Some prescribing advice in this guidance, has been locally agreed with specialists from NUH and SFH hospitals and may differ from the advice included by the manufacturers in the summary of product characteristics (SmPC).

Apixaban is the most cost effective DOAC (twice a day dose) and should be used first line unless there is a clinical reason for using another DOAC. Rivaroxaban is the second line DOAC locally (once daily dose).

## Assessing patients for anticoagulation in AF

(This guidance applies to patients with non-valvular paroxysmal, persistant or permanent AF, atrial flutter or





where a DOAC is the most appropriate anticoagulant, apixaban is the most cost effective DOAC (twice a day dose) and should
be used first line for patients with NVAF unless there is a specific clinical reason not to do so. Rivaroxaban is the second line
DOAC locally (once daily dose). In line with NICE guidance, other DOACs can be considered. The following patient factors may
suggest a preferred DOAC.

Renal impairment	Local specialists recommend avoiding DOACs in patients with CrCl<15mL/min due to increased risk of drug accumulation and bleeding. Apixaban has the lowest renal excretion percentage of all the DOACs and may be used at reduced dose (2.5mg BD) with caution if CrCl is <30mL/min and >15mL/min. Dabigatran is contraindicated if CrCL<30ml/min. See <u>appendix 1</u> for more information of dosing.
High creatinine clearance (>95ml/min)	<b>Edoxaban</b> – shows <b>decreased efficacy</b> at high creatinine clearance. The local advice is that patients already established on edoxaban and later found to have a CrCl >95ml/min, should have their anticoagulation plan reviewed and switched onto an alternative DOAC. The decision to treat a patient with NVAF and high CrCl with edoxaban ultimately lies with the prescriber after taking into consideration the patient's thromboembolic and bleeding risk.
Increased bleeding risk (Orbit Score ≥4 or HAS-BLED ≥3 )	Apixaban
Patients > 75 years old	Local specialists advise caution in using Dabigatran due to concern about increased risk of gastrointestinal bleeding.
Patients >120kg	Use other DOACs (NOT edoxaban) or warfarin if over 150kg.
Patient requires compliance aid	Apixaban, rivaroxaban or edoxaban (NOT dabigatran).
Swallowing difficulties / enteral feeding tubes	Edoxaban, Apixaban or Rivaroxaban. <b>Poor oral intake or inability to take with food can</b> cause treatment failure with rivaroxaban.

### Checklist and process for initiation of all anticoagulants:

#### Initiation points

Inform the patient of indication for the new medicine, dose, frequency, duration of therapy

Emphasise importance of concordance to therapy especially with shorter acting agents (DOACs)

Discuss possible undesirable effects


Inform patient what to do if they miss a dose

Discuss what to do in the event of injury / bleeding

Advise patient to inform all healthcare professionals and to discuss OTC medicines with pharmacist (avoid aspirin/NSAIDs)

Provide patient with an alert card (usually comes from the manufacturer)

Recommend the patient to discuss this new medicine with their pharmacist as part of the free <u>new medicines</u> <u>service</u>



### **DOACs** – monitoring and reviewing

- Unlike warfarin, a prothrombin time may not be sensitive to their anticoagulant effect. Likewise, an INR will not
  demonstrate the level of anticoagulation.
- As DOACs are predominantly eliminated by the renal route, it is recommended to monitor the renal function of a patient taking a DOAC. The following regimen is broadly in line with NICE guidance on Chronic Kidney Disease and based on consensus clinician opinion. This may recommend more frequent monitoring than that advised in the manufacturer's summary of product characteristics.

	Baseline blood tests					
	Liver function tests					
Patient group	<u>clearance</u> )					
All		✓	1	<b>√</b>		
monthly thereafter. Follo	w up intervals may vary	DAC treatment is started, are depending on the individua on blood monitoring during	al patient's characterist	cics, comorbidities and co-		
	U + Es ( <u>Creatinine</u>	Full blood count	Coagulation screen	Liver function tests		
Patient group	clearance)					
Creatinine Clearance > 60ml/min	Annually*	Annually*	X Inappropriate without correct reagent	Annually*		
If the person is frail or older than 75 years <sup>28</sup>	6 monthly	6 monthly	X Inappropriate without correct reagent	6 monthly		
Creatinine Clearance <b>30-60ml/min</b> **	Minimum 6 monthly**	Minimum 6 monthly**	X Inappropriate without correct reagent	Minimum 6 monthly**		
Creatinine Clearance 15-30ml/min	3 monthly***	3 monthly***	X Inappropriate without correct reagent	3 monthly***		

\* In addition to adequate clinical surveillance, laboratory testing of haemoglobin/haematocrit could be of value to detect occult bleeding, as judged to be appropriate.

\*\* <u>NICE CKS</u> and <u>SPS</u> recommend that if CrCl < 60 mL/min, the frequency of monitoring (in months) can be guided by the CrCl divided by 10. For example, every 3 months if CrCl is 30 mL/minute.

\*\*\* <u>PCCS and UKCPA</u> recommend routine surveillance every 6 months in patients over 75 years of age and/or frail and routine surveillance 3 monthly in CrCl 15-30mls/min.

- Weight should be reviewed annually for any renal function calculations to remain accurate.
- Initial clinical trials only included patients between 50kg and 120kg, but there is increasing evidence that these medications can safely be used up to 150kg<sup>19,20,21,22</sup>
- The local consensus from our specialists is to use any of the DOACs in patients under 150kg (except edoxaban not used in patients over 120kg) irrespective of indication for anticoagulation. Rivaroxaban or apixaban can be used in patients above 150kg who have had DVT or PE only (not for indication of AF).
- <u>Creatinine clearance</u> must be used for calculating renal function using the Cockcroft and Gault equation (see below). eGFR is not a suitable alternative:

CrCl (ml/min)=<u>(140 – age) x wt (kg)</u> x 1.04 (female) or 1.23 (male)

serum creatinine (micromole/l)

- For DOAC monitoring, calculate creatinine clearance (CrCl) using the actual body weight from last 12 months (unless recent weight loss/gain). Use adjusted bodyweight if patients > 120kg / BMI > 40.<sup>8</sup>
- NB The clinical systems used in Nottinghamshire in primary care (SystmOne and EMIS) have an inbuilt Cockcroft-Gault based renal function calculator which can be used to dose DOACs. The most up to date values for the patient's actual body weight and height will have to be inserted. It should be remembered that all values are estimates of renal function.

### **DOACs – Further information on calculating Creatinine Clearance**

SystmOne CrCl calculator uses:	EMIS CrCl calculator uses:
From November 2023 the SystmOne renal calculator	- actual body weight for CrCl calculation for patients taking
highlights the dates for when the weight and the creatinine	apixaban, edoxaban or rivaroxaban
value were last recorded and gives three values for the CrCl	- and ideal body weight for dabigatran.
using: ideal, actual, and adjusted body weight.	There is text information added to advise whether actual or
	IBW has been used each time a calculation is made.

- Alternatively, <u>MD+ Calc Creatinine Clearance Calculator</u> can be used (can be downloaded as an app to an apple or android device), which gives values for IBW, Adjusted BW and Actual weight. Always use the most up to date values and check the default units are correct when entering weight, serum creatinine and height. It would be good practice for the clinician reviewing the patient to document what method was used.
- If you have concerns about dose adjustments for DOACs based on estimating renal function using Cockcroft Gault, please seek advice from your local specialists.

#### Points for discussion during a DOAC review

- Assess adherence to treatment.
- Look for signs of bleeding or anaemia.
- Ask about other adverse effects of DOAC.
- Assess for features of thromboembolic events, such as symptoms of stroke, or breathlessness (which may suggest a pulmonary embolism). See the CKS topics on <u>Stroke and TIA</u> and <u>Pulmonary embolism</u> for more information.
- Ask about the use of other medications, including over-the-counter (OTC) products, to identify possible drug interactions with DOAC.
- Assess and minimize modifiable risk factors for bleeding, such as uncontrolled hypertension, medication predisposing for bleeding (such as aspirin), and excessive alcohol intake.
- Give appropriate information and advice on DOAC treatment.


### Criteria for review and discontinuation of DOACs:

**Should the individual patient be deemed at a greater risk of developing renal dysfunction, more frequent monitoring may be warranted.** The frequency of testing will need to be increased if there is rapid progression, or during inter-current illness and peri-operatively in all patients with CKD.

Side Effect	Action
Haemorrhage	Refer patient immediately to Accident and Emergency (A&E) if serious
	bleeding occurs e.g. GI bleeding, epistaxis lasting more than 1 hr
Dyspepsia	Common with dabigatran. Consider a proton pump inhibitor. If persists
	consider alternative anticoagulant.
Unexplained acute fall in haemoglobin or	Refer patient immediately to A&E for investigation
blood pressure	
Trauma (especially to the head)	Consider referral to A&E
Excessive bruising	Seek immediate haematologist advice
Any acute illness that MAY affect renal	Measure U+Es and calculate creatinine clearance. Reduce dose or
function	withhold treatment if required. Consider seeking advice regarding
	restarting treatment from the local anticoagulation service
Significant reduction in renal function, but	Reduce dose as appropriate according to the medicine's recommended
CrCl still >30mL/min (and see below)	dosing schedule in renal impairment (see above for CrCl calculation). If
	renal function continues to worsen discuss with haematologist.
Fall in creatinine clearance to <30mL/min	Stop DOAC, assess for bleeding and seek advice as to whether specific
with dabigatran, or <15mL/min with	assays are indicated / alternative anticoagulation required.
apixaban, rivaroxaban, edoxaban	Note that local specialists recommend avoiding DOACs in patients with
	Creatinine Clearance CrCL<15ml/min (for dabigatran avoid if
	CrCL<30mL/min) due to increased risk of accumulation and bleeding.
	Apixaban has the lowest renal excretion percentage of all the DOACs and
	may be used with caution at reduced dose (2.5mg BD) if CrCl is
	<30mL/min and >15mL/min.

### Warfarin – monitoring and reviewing.

For adults with AF already taking warfarin and are stable, continue with current medication and discuss the option of switching treatment at their next routine appointment, considering contraindication to DOACS and the person's time in therapeutic range. In view of the results from recent FRAIL-AF trial, if an elderly patient (over 75) is already established on warfarin (and their TTR is good), we do not necessarily change them to a DOAC. In addition, if there is a need to change them to a DOAC, consider avoiding Dabigatran due to the risk of catastrophic bleed in the elderly.



### References

- 1. NICE NG196: Atrial Fibrillation: diagnosis and management. April 2021, last updated June 2021.
- 2. Warfarin Summary of Product Characteristics. Last updated 10/12/2021 see <u>www.medicines.org.uk</u>
- 3. Xarelto Summary of Product Characteristics. Last updated 09/08/2022 see <u>www.medicines.org.uk</u>
- 4. Eliquis Summary of Product Characteristics. Last updated 03/05/2022 see <u>www.medicines.org.uk</u>
- 5. Pradaxa Summary of Product Characteristics. Last updated 15/09/2022 see www.medicines.org.uk
- 6. Lixiana Summary of Product Characteristics. Last updated 22/04/2022 see <u>www.medicines.org.uk</u>
- DOACs Monitoring SPS Guidance <u>DOACs (Direct Oral Anticoagulants) monitoring SPS Specialist Pharmacy</u> <u>Service – The first stop for professional medicines advice</u>. Accessed Nov 2022.
- 8. <u>UKCPA Anticoagulation for non-valvular AF following NHSE DOAC commissioning recommendations. July</u> 2022 Accessed on pcpa.org.uk November 22.
- 9. PCCS MAIN WEBSITE fsnew-generic (pccsuk.org)
- 10. The Renal Drug Database. Accessed 13/08/2014
- 11. NICE Clinical Guideline 144: Venous thromboembolic diseases: the management of venous thromboembolic diseases and the role of thrombophilia testing. June 2012.
- 12. BNF November 23. Available from BNF (British National Formulary) | NICE
- 13. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation (an update of the 2010 ESC Guidelines for the management of atrial fibrillation) European Heart Journal 2012;33:2719-2747 available from: <a href="http://www.escardio.org/guidelines-surveys/esc-guidelines/Pages/atrial-fibrillation.aspx">http://www.escardio.org/guidelines-surveys/esc-guidelines/Pages/atrial-fibrillation.aspx</a>
- 14. NICE Clinical Guideline 73: Chronic Kidney Disease. September 2008
- 15. NICE Clinical Guideline 182: Chronic Kidney Disease. July 2014
- 16. NICE: Stroke and systemic embolism (prevention, non-valvular atrial fibrillation) apixaban (TA275) Feb 2013. Available at <u>http://www.nice.org.uk/guidance/TA275</u>
- 17. NICE: Rivaroxaban for the prevention of stroke and systemic embolism in people with atrial fibrillation (TA256) May 2012. Available at <u>http://www.nice.org.uk/guidance/TA256</u>
- 18. NICE: Dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation (TA249) March 2012. Available at <u>http://www.nice.org.uk/guidance/TA249</u>
- 19. MHRA Drug Safety Update October 2013: New oral anticoagulants apixaban (Eliquis ▼), dabigatran (Pradaxa) and rivaroxaban (Xarelto ▼): risk of serious haemorrhage—clarified contraindications apply to all three medicines. Available at: <u>http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON322347</u>
- 20. Pisters et al, A novel user-friendly score (HAS-BLED) to assess 1-Year risk of major bleeding in patients with Atrial Fibrillation (2010) CHEST: 138(5); 1093-1100 http://journal.publications.chestnet.org/data/Journals/CHEST/20451/100134.pdf
- Martin K, Beyer-Westendorf J, Davidson BL, Huisman MV, Sandset PM, Moll S. Use of the direct oral anticoagulants in obese patients: guidance from the SSC of the ISTH. Journal of thrombosis and haemostasis. 2016; 14(6):1308-1313. doi.org/10.1111/jth.13323
- Marin K et al. Use of direct oral anticoagulants in patients with obesity for treatment and prevention of venous thromboembolism: Updated communication from the ISTH SSC Subcommittee on Control of Anticoagulation. Journal of Thrombosis and Haemostasis. Aug 2021; 19(8): 1845-2098. <u>https://doi.org/10.1111/jth.15358</u>
- 23. De Caterina R, Lip GYH. The non-vitamin K antagonist oral anticoagulants (NOACs) and extremes of body weight-a systematic literature review. Clin Res Cardiol. 2017 Aug; 106(8):565-572. doi: 10.1007/s00392-017-1102-5. Epub 2017 Apr 10. Review.
- Tittl L, Endig S, Marten S, Reitter A, Beyer-Westendorf I, Beyer-Westendorf J. Impact of BMI on clinical outcomes of NOAC therapy in daily care - Results of the prospective Dresden NOAC Registry (NCT01588119). Int J Cardiol. 2018 Jul 1; 262:85-91. <u>doi: 10.1016/j.ijcard.2018.03.060.</u> Epub 2018 Mar 14.
- Peterson ED et al. Comparative effectiveness, safety, and costs of rivaroxaban and warfarin among morbidly obese patients with atrial fibrillation. American Heart Journal. Nov 2018. 212 (0): 113-19. <u>https://doi.org/10.1016/j.ahj.2019.02.001. Epub 2019 Feb 20</u>.
- 26. Joosten LPT et all, Safety of Switching from a Vitamin K Antagonist to a Non-Vitamin K Antagonist Oral Anticoagulant in Frail Older Patients with Atrial Fibrillation: Results of the FRAIL-AF Randomized Controlled Trial . American Heart Association. Aug 2023. <u>https://doi.org/10.1161/CIRCULATIONAHA.123.066485</u>
- 27. NICE CKS Anticoagulation oral: Management. (Oct 2023) Management | Anticoagulation oral | CKS | NICE
- 28. NHS England Operational note: Commissioning recommendations for national procurement for direct-acting oral anticoagulant(s) (DOACs). (Jan 24) <u>NHS England » Operational note: Commissioning recommendations for national procurement for direct-acting oral anticoagulant(s) (DOACs)</u>

Medicine	Apixaban	Dabigatran	Edoxaban	Rivaroxaban		
Mechanism of Action	Factor Xa inhibitor	Direct thrombin inhibitor	Factor Xa inhibitor	Factor Xa inhibitor		
		110mg and 150mg hard capsules NB. 75mg capsules are not licensed for AF.	15, 30 and 60mg film coated tablets	15 and 20mg film coated tablets. NB. 10mg and 2.5mg tablets are not licensed for AF.		
Licensed Doses	5mg TWICE daily	150mg TWICE daily	60mg ONCE daily	20 mg ONCE daily		
(NB applies to AF						
indication only)	Reduced to 2.5 mg twice daily if at least <i>two</i> of the following: - age ≥ 80 years, - body weight ≤ 60 kg, or - serum creatinine ≥ 133 micromole/L	Reduced to 110mg twice daily if patient is: - ≥ 80 years* or taking verapamil; - aged between 75-80 years**; - moderate renal impairment (CrCl 30-50 mL/min); - gastritis, esophagitis or gastro-esophageal reflux; - increased risk of bleeding. * Local specialists advise caution in using Dabigatran in patients over 75 years old, due to concern about increased risk of gastrointestinal bleeding.	Reduced to 30mg once daily if -CrCl 15-50mL/min -low body weight (≤60kg), concomitant use of potent P- gp inhibitors (e.g. Dronaderone, Erythromycin, Ketoconazole, Ciclosporin).	Reduced to 15 mg once daily if CrCl <50mL/min		
Use in renal impairment	Renal function should be assessed prior to DOAC treatment in all patients.					
	• DOACs can be used in patients with renal impairment in line with the SPC of the specific agent (as below).					
	<ul> <li>Patients who develop acute renal failure should discontinue the DOAC and seek specialist advice</li> </ul>					
	• Creatinine clearance must be calculated (see here for calculator), eGFR is <b>NOT</b> considered a suitable alternative.					
Licensed doses in renal	CrCl 15-29mL/min:	CrCl < 30mL/min: Contraindicated	CrCl >95ml/min: DO NOT use	CrCl 15-49 mL/min: 15 mg OD		
impairment	2.5mg BD (use with caution) CrCl < 15mL/min: Contraindicated		edoxaban, shows decreased efficacy at high creatinine clearance. CrCl 15-50mL/min: 30mg OD CrCl <15mL/min: Contraindicated	CrCl < 15mL/min: Contraindicated		
Extremes of body weight	Initial clinical trials only included patients between 50kg and 120kg, but there is increasing evidence that these medications can safely be used up to 150kg <sup>1,2,3</sup>					
,	The local consensus from our specialists is to use any of the DOACs in patients under 150kg (except edoxaban – not used in patients over 120kg) irrespective indication for anticoagulation. Rivaroxaban or apixaban can be used in patients above 150kg who have had DVT or PE only (ie <b>not in context of AF</b> ).					
Use in hepatic	Check <u>spc</u> .	Check <u>spc</u> .	Check <u>spc</u> .	Check <u>spc</u> .		
impairment						

# Appendix 1: Anticoagulant comparison Alphabetical; For more detailed information, refer to manufacturers Summary of Product Characteristics (SPCs)

Medicine	Apixaban	Dabigatran	Edoxaban	Rivaroxaban
Administration	Swallowed with water, with or without food.	Take with or without	Take with or without food. Swallow	The tablet is taken with food. Poor oral
		food. Swallow whole	whole with a glass of water, to	intake or inability to take with food can
		with a glass of water,	facilitate delivery to the stomach.	cause treatment failure with rivaroxaban.
		to facilitate delivery to		
		the stomach.		
Food interactions	No specific foods known to interact – see adminis Poor oral intake or inability to take with food ca			
Suitability for patients with	Tablets may be crushed and suspended in	Capsules should not be	For patients who are unable to	Granules for oral suspension are licensed
swallowing difficulties/	water, or 5% glucose in water (G5W), or apple	opened- increased risk	swallow whole tablets, tablets may	for nasogastric and PEG tubes.
enteral tubes	juice or mixed with apple puree and immediately administered orally - suspension stable for up to 4 hours. Alternatively, tablets can be crushed and suspended in 60mL of water or G5W and delivered immediately through a nasogastric tube. (Licenced route of administration)	of bleeding (oral bioavailability may be increased by <b>75 %</b> when the pellets are removed from the capsule shell).	be crushed and mixed with water or apple puree and immediately administered orally. Alternatively, tablets may be crushed and suspended in a small amount of water and immediately delivered through a gastric tube after which it should be flushed with water. (Licenced route of administration) Crushed tablets are stable in water and apple puree for up to 4 hours.	Not suitable for administration via enteral feeding tubes terminating beyond the stomach (i.e. in the duodenum or jejunum) due to decreased absorption when given in this manner and thus not appropriate for NJ / PEJ / PEGJ tubes. For patients who are unable to swallow whole tablets, tablets may be crushed and mixed with water or apple puree immediately prior to use and administered orally. After the administration of crushed film-coated tablets, the dose should be immediately followed by food. The crushed tablet may also be given through gastric tubes.
Suitability for patients with	Shorter half-life of DOACs may mean missed dose	s result in more time with	 out anticoagulation Difficult to measu	
compliance problems			Sat anticologuation. Difficult to medau	
	May be put in MCAs (no special storage	Not suitable for use in	May be put in MCAs (no special	May be put in MCAs (no special storage
	conditions required)	MCAs (unstable out of	storage conditions required)	conditions required)
		original packaging)		
Reversibility (a separate	Yes. Approved as per <u>NICE TA 697</u> for life-	Yes	No specific reversal agent. No real	Yes. Approved as per <u>NICE TA 697</u> for life-
guideline is available in	threatening or uncontrolled bleeding only if the		evidence or experience on reversal.	threatening or uncontrolled bleeding only if
secondary care)	bleed is in the gastrointestinal tract. There is			the bleed is in the gastrointestinal tract.
	an ongoing clinical trial for intracranial			There is an ongoing clinical trial for
	haemorrhage for eligible patients at SFH. See			intracranial haemorrhage for eligible
	formulary.			patients at SFH. See formulary.

Medicine		Apixaban	Dabigatran	Edoxaban	Rivaroxaban
Contraindications		Hypersensitivity to drug or excipients			·
		<ul> <li>Active clinically significant bleeding.</li> </ul>			
		<ul> <li>Risk factors for major bleeding e.g. cu</li> </ul>	irrent or recent gastrointestinal ulco	eration, presence of malignant neopl	asms at high risk of
		bleeding, recent brain or spinal injury, i	recent brain, spinal or ophthalmic s	urgery, recent intracranial haemorrh	age, known or
		suspected oesophageal varices, arterio	venous malformations, vascular and	eurysms or major intraspinal or intra	cerebral vascular
		abnormalities.			
		<ul> <li>In patients with prosthetic heart valve</li> </ul>	es.		
		• In uncontrolled severe hypertension,	during pregnancy and breast feeding	ng.	
		<ul> <li>Not recommended in prosthetic hear</li> </ul>	t valves, moderate to severe mitral	stenosis, haemodynamically instable	PE, patients
		requiring thrombolysis or embolectomy	y for PE or those with active cancer		
<b>Drug Interactions</b>	- refer to SPC	Dabigatran and edoxaban are substra	ites for P-glycoprotein (P-gp)		
for more informat	ion	Apixaban and rivaroxaban are metabo	olised by cytochrome P450 enzyme	CYP3A4 and are substrates for P-gp.	
Class	Medicine	The table below outlines main DOAC dr	rug interactions (drugs in bold font	recommend not be used with DOACs	<ul> <li>except those marked</li> </ul>
		with * can be used with edoxaban):			
		N.B. This is not an exh	austive list and if in doubt check fo	or interactions using BNF, SmPC or or	nline interaction checker
Strong	*Ciclosporin	Strong recommendation not to use	Combination contraindicated.	Reduce dose to 30mg	Strong recommendation not to use
P-gp inhibitors	*Dronaderone			daily if on ciclosporin,	
(also CYP3A4	Itraconazole			dronaderone,	
inhibitors)	*Ketoconazole			erythromycin or	
	Posaconazole			ketoconazole.	
	Tacrolimus			Recommend not use with	
	Voriconazole			others listed.	
	Imatinib				
	Crizotinib				
	Vandetanib				
	Sunitinib				
	Abiraterone				
Other strong	Amiodarone	Caution.	Caution. If on verapamil give	Caution.	Caution.
P-gp inhibitors	Clarithromycin		110mg twice daily.		
(also CYP3A4	Quinidine				
inhibitors)	Verapamil				
HIV Protease	Ritonavir	Strong recommendation not to use.	Concomitant use not	Not recommended to use.	Strong recommendation not to use.
inhibitors (P-gp	Telaprevir		recommended.		
inhibitors and	Lopinavir				

CYP3A4	Darunavir				
inhibitors)	Cobicistat				
Strong P-gp	Carbamazepine	Combination should be avoided.			
and CYP3A4	Phenobarbital				
inducers	Phenytoin				
	Primidone				
	Rifampicin				
	St John's Wort				
	Vinblastine				
	Doxorubicin				
	Enzalutamide				
Other	E.g. LMWH,		Combination contraindicated	d except when switching therapy or	
anticoagulants	warfarin, UFH,			ecessary to maintain an open central	
-	fondaparinux		-	arterial catheter	
Others	Aspirin	Caution. Combination n	ot recommended. A careful risk-b	enefit assessment should be made pri-	or to initiation if required.
	Clopidogrel				
	NSAID's				
	Prasugrel		Combination	not recommended.	
	Ticagrelor				
	SSRI's and		Caution. Monito	or for signs of bleeding.	
	SNRI's				
Pregnancy and bre	eastfeeding - refer	Not recommended during	Should not be used during	Not recommended during	Contraindicated in pregnancy
to specialist antico	agulation	pregnancy.	pregnancy unless clearly	pregnancy.	and breast feeding.
services.		A decision must be made to either	necessary.	Edoxaban is contraindicated	
		discontinue breast-feeding or to	Breast-feeding should be	during breast-feeding.	
		discontinue/abstain from apixaban	discontinued during	A decision must be made to	
		therapy.	treatment.	discontinue breast-feeding or to	
				discontinue/abstain from	
				therapy.	

Medicine	Warfarin <sup>1</sup>
Presentation	3mg tablets are used in Nottinghamshire (other strengths may be used in other areas)
Licensed Indication	Prophylaxis of systemic embolism in patients with atrial fibrillation.
<b>Dosing</b> (NB applies to AF indication only)	Variable depending on INR (international normalised ratio)
Use in renal impairment	Dose as per INR as in normal renal function <sup>5</sup>
Use in hepatic impairment	Should be avoided in severe hepatic impairment, especially if prothrombin time is already prolonged.
Administration	Take at the same time each day.
Suitability for patients with swallowing difficulties/ enteral tubes	May be crushed and dispersed for enteral tube administration (outside of license) Suspension is not licensed for enteral tube administration.
Contraindications	<ul> <li>Hypersensitivity</li> <li>Haemorrhagic stroke</li> <li>Clinically significant bleeding</li> <li>Within 72 hours of major surgery with risk of severe bleeding</li> </ul>
Drug Interactions- refer to SPC for more information Food interactions	Many- <i>refer to BNF or SPC</i> With INR monitoring warfarin doses can be adjusted to maintain anticoagulation during therapy with many concomitant interacting medicines INR altered by some food/ drink
Common side effects Suitability for patients with compliance problems	See Summary of Product characteristics Some patients may struggle with variability of dosing. INR gives indication of compliance. Generally considered not suitable for multi-compartment compliance aids (MCAs) due to variability of dosing, but may be considered if a mechanism of managing dose changes is assured
Mechanism of Action	Inhibitor of clotting factors II, VII, IX & X
Extremes of body weight	Dose as per INR
<b>Reversibility</b> (a separate guideline is available in secondary care)	Yes
<b>Pregnancy and breastfeeding-</b> <i>refer to</i> <i>specialist anticoagulation services</i>	Contraindicated in the first and third trimesters of pregnancy and within 48 hours postpartum. Warfarin can be used during breast-feeding.

**Appendix 2: Warfarin** (For more detailed information, refer to manufacturers Summary of Product Characteristics (SPCs)

### Appendix 3: Switching anticoagulant therapy for non-valvular AF patients only

	Apixaban	Dabigatran	Edoxaban	Rivaroxaban	
Warfarin		Inform the pati	ient's anticoagulation clinic if switching away from warfarin.		
to DOAC	Stop warfarin and initiate apixaban when INR is $\leq$ 2.0.	Stop warfarin and initiate dabigatran when INR is ≤ 2.0.	Discontinue warfarin and start edoxaban when the INR is $\leq 2.5$	Stop warfarin and initiate rivaroxaban when INR is ≤ 3.0.	
Oral to parenteral anticoagulant*	Give the first dose of parenteral anticoagulant at the time the next apixaban dose would be taken.	Wait 12 hours after the last dose of dabigatran before switching to a parenteral anticoagulant	Discontinue edoxaban and start the parenteral anticoagulant at the time of the next dose of edoxaban	Give the first dose of parenteral anticoagulant at the time the next rivaroxaban dose would be taken.	
Parenteral anticoagulants to oral anticoagulant**	Give the first dose of apixaban at the time the next parenteral anticoagulant dose is due.		LMWH: Discontinue LMWH and start edoxaban at the time of the next scheduled administration of LMWH UFH: Discontinue the infusion and start edoxaban 4 hours later	LMWH: Start rivaroxaban 0 to 2 hours before the time of the next scheduled dose UFH: Start rivaroxaban at the time of discontinuation of UFH	
DOAC to Warfarin	Discuss with local anticoagulation service before switching depending on local pathway for warfarin initiation and monitoring (below information is a guide if prescriber is responsible for coumarin monitoring)				
	Give warfarin and apixaban concurrently until the INR is ≥ 2.0.	Adjust the starting time of warfarin based on CrCl as follows: • CrCl ≥ 50 mL/min, start	<ul> <li><u>Oral option:</u> For patients taking:</li> <li>60 mg of edoxaban, reduce the dose to 30 mg and begin warfarin concomitantly.</li> <li>30 mg of edoxaban, reduce the dose to 15 mg and begin</li> </ul>	Give warfarin and rivaroxaban concurrently until the INR is ≥ 2.0. Initiate warfarin at standard dose	
	Initiate warfarin at standard dose for 2 days and then dose as per INR. Obtain an INR prior to the next scheduled dose of apixaban.	warfarin 3 days before discontinuing dabigatran • CrCl ≥ 30-49 mL/min, start warfarin 2 days before discontinuing dabigatran	warfarin concomitantly. INR must be measured at least weekly and just prior to the daily dose of edoxaban to minimize the influence of edoxaban on INR measurements. INRs should be taken immediately before the next DOAC dose as all Xa inhibitors can variably prolong the PT.	for 2 days and then dose as per INR. INRs should be taken at least 24hrs after the previous dose of rivaroxaban (immediately before the) next dose.	
	INRs should be taken immediately before the next DOAC dose as all Xa inhibitors can variably prolong the PT.	INRs may be falsely elevated until dabigatran has been stopped for at least 2 days. Until then, INR values should be	<ul> <li>Once a stable INR ≥ 2.0 is achieved, edoxaban should be discontinued and the warfarin continued.</li> <li><u>Parenteral option:</u></li> <li>Discontinue edoxaban and administer a parenteral anticoagulant and warfarin at the time of the next scheduled edoxaban dose.</li> </ul>	INRs may be falsely elevated during rivaroxaban therapy, but once rivaroxaban is discontinued, may be done reliably at least 24 hours after the last dose.	
		interpreted with caution.	Once a stable INR $\geq$ 2.0 is achieved the parenteral anticoagulant should be discontinued and the warfarin continued.		

(NB that this information applies to non-valvular AF indication only- see SPCs for alternative indications)

Key: LMWH = low molecular weight heparin (e.g. enoxaparin), UFH = unfractionated heparin

\*For Warfarin parenteral anticoagulant can be started immediately.

\*\*Warfarin can be given concomitantly with parenteral anticoagulant. Concomitant therapy may be required until therapeutic level achieved or as per local policy.

#### Appendix 4: Notes on HAS-BLED score

Assess bleeding risk using HAS-BLED score		
Feature	Score	
Hypertension (uncontrolled SBP >160mmHg)	1	
Liver disease (Cirrhosis or bilirubin >2x normal with AST/ALT/ALP >3x normal)	1	
Renal disease (Dialysis, transplant, or >200 micromol/L)	1	
Stroke history	1	
Bleeding history or predisposition (e.g. anaemia)	1	
Labile INRs (i.e. Time in Therapeutic Range < 60%)	1	
Elderly (e.g. age > 65 years or frail condition)	1	
Drugs (concomitant antiplatelets, NSAIDs etc.) or alcohol abuse (1 point each)	1 or 2	
Score: (maximum score of 9) Address modifiable risks where possible		

Martin K, Beyer-Westendorf J, Davidson BL, Huisman MV, Sandset PM,

Moll S. Use of the direct oral anticoagulants in obese patients: guidance from the SSC of the ISTH. Journal of thrombosis and haemostasis aemos.

The HAS-BLED score estimates the 1-year risk for major bleeding (intracranial, hospitalization, haemoglobin decrease > 2 g/L, and/or transfusion)  $^{1}$ 

"HAS-BLED should not be used on its own to exclude patients from oral anticoagulant therapy; it allows the clinician to identify bleeding risk factors and to correct those that are modifiable, i.e. by controlling blood pressure, removing concomitant antiplatelet or nonsteroidal anti-inflammatory medicines, and counseling the patient about reducing alcohol intake (if excessive). Thus, bleeding risk assessment with HAS-BLED should not be used as an excuse not to prescribe oral anticoagulant, but rather to highlight those patients in whom caution with such treatment and regular review is warranted". <sup>2</sup>

A HAS-BLED score of  $\geq$ 3 indicates that caution is warranted when prescribing oral anticoagulation and regular review is recommended. <sup>1</sup>

HAS-BLED score total points	Major Bleeding Risk (% per annum)	Risk description
0	1.13	Low
1	1.02	
2	1.88	Moderate
A HAS-BLED score of $\geq$ 3 indicates that caution is warranted when prescribing oral anticoagulation		
and regular review is recommended.		
3	3.74	
4	8.70	High
5 to 9	Insufficient data	

2. De Caterina R, Lip GYH. The non-vitamin K antagonist oral anticoagulants (NOACs) and extremes of body weight-a systematic literature review. Clin Res Cardiol. 2017 Aug; 106(8):565-572. doi: 10.1007/s00392-017-1102-5. Epub 2017 Apr 10. Review.

3. <u>Tittl L, Endig S, Marten S, Reitter A, Beyer-Westendorf I, Beyer-Westendorf J. Impact of BMI on clinical outcomes of NOAC therapy in daily care - Results of the prospective Dresden NOAC Registry (NCT01588119). Int J Cardiol. 2018 Jul 1; 262:85-91. doi: 10.1016/j.ijcard.2018.03.060. Epub 2018 Mar 14.</u>

4. Pisters R, Lane DA, Nieuwlaat R et al. A novel user-friendly score (HAS-BLED) to assess one-year risk of major bleeding in atrial fibrillation patients: The Euro Heart Survey. Chest 2010

5. Lane DA, Lip GYH. Circulation 2012; 126: 860-865.

2016; 14(6):1308-1313. doi.org/10.1111/jth.13323

1.

6. NICE CKS Anticoagulation – oral. Last revised in October 2023.